Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers

Size: px
Start display at page:

Download "Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers"

Transcription

1 Rationale & Strategy For Integrating Buprenorphine Treatment Into Community Health Centers Marwan S. Haddad, M.D. Community Health Center, Inc. Connecticut September 16, 2008

2 Community Health Center, Inc. 164 Community and School Based Sites

3 Medical Pediatrics Internal medicine Family practice Family planning Breast and Cervical Cancer Early Detection Program Asthma management program Prenatal program Dental Maternal-Infant program Preventative Restorative Emergency Mobile dentistry in schools Eligibility Assistance Language Line interpretation Services Services We Provide Behavioral Health Children Adults Families School Based Health Centers Medical Behavioral Health Dental HIV/AIDS AIDS/HIV Services Medical, behavioral, social Domestic Violence Services Domestic Violence Services Battered Women s Shelter Community Contributions Vinnie s Jump & Jive HomeRoom after school program Family Wellness Center

4 Outline Buprenorphine: What is it? Integrated Healthcare Theoretical Models of Care/BHIVES CHC Model

5 Buprenorphine Partial opioid agonist at the mu receptor It has a ceiling effect at moderate doses It has a high affinity for the opioid receptor It has a slow dissociation rate from the opioid receptor Must be taken sublingually Is usually co-administered with naloxone as Suboxone May be prescribed by the primary physician if 8 hour course completed

6 39 year old male Using heroin for the last 14 years Injecting for the last 10 years Patient MH Has been erratically in care and in ERs (abscesses, anxiety, overdose) over 12 years Methadone program for 8 months kicked out because of continued cocaine use

7 Case Continued Heard about the buprenorphine program at CHC Interested in enrolling in program Tried buprenorphine off the streets and thought it worked really well for him Called the front desk and asked for an appointment with the doctor who does Suboxone

8 Front Desk Substance abuse counselor Initial MD Assessment for BPN Program CHC Providers HIV Program Mental Health

9 Initial Assessment: 1-2 History (determination for opioid dependence) Focused Physical Baseline phlebotomy including routine HIV and viral hepatitis screening Urine toxicology and pregnancy screening Screening for mental illness Explanation of buprenorphine/naloxone How and why it works How to take it Side effects Precautions (benzodiazepines) Induction phase (requires being in withdrawal) Stabilization phase Maintenance phase

10 Initial Assessment (cont) Suboxone Program description and expectations Honesty Respect of all staff Urine tox screens, supervised Substance abuse counseling Frequency of visits Contracts and Agreements signed (this could be done at the initial assessment visits by MD or RN or by substance abuse counselor)

11 Three agreements that patients sign Explanation of the program Contract Release with the pharmacy Contracts & Nurse or substance abuse counselor has these signed by the patient Copies of agreements available if interested

12 Conundrums In Buprenorphine Clinic organizational constraints (scheduling, ancillary services, etc.) Clinician autonomy (individual preferences vs. programmatic approach, numbers of patients on program) Urgency of the patient s needs (IDU vs. non-idu, addiction severity, etc.) Working closely with a single pharmacy

13 Voucher System Voucher system designed to reduce diversion and improve retention in counseling and care Voucher is embossed and signed by the patient and staff member Coordinate with one pharmacy Allows various team members (MD, counselor or nurse) to approve continued buprenorphine treatment based upon contingency management

14 Induction Visit Comes in in withdrawal, having last used 16 hours before Had objective signs and symptoms of opioid withdrawal (COWS): Irritable but pleasant; myalgias, runny nose, abdominal pains Patient given an initial voucher for suboxone and he goes to pick it up at the pharmacy across from the health center First dose is observed in the clinic

15 Sublingual administration Preparation For Abstinence symptoms do NOT disappear immediately, but don t typically worsen (BE PATIENT!) Vistaril 50mg often used for the first few days to help with insomnia Most patients will try to get high, but soon learn that there is no benefit from using opiates with BPN

16 Initially, received 4mg as observed dose Induction Day 1 Instructed to hang around for about 45 minutes If feeling fine then, could leave for the rest of the day Instructed to take another 4 mg in about 1-2 hours Encouraged to call in toward the end of the day to report how he was doing, particularly if not doing well Instructed to return the next day for a dose determination

17 Nursing assessment of previous 24 hours Did well overnight Induction Day 2 Took another 4 mg last evening and 8 mg this morning Used ii 50mg Vistaril and helped take the edge off and slept 6 hours She gives him a voucher for ii 8mg pills per day for 1 week with her and 2 week follow-up with MD

18 Still craving a little 1 Week Nursing Finding by the end of the day, beginning to feel jittery and anxious. Nurse speaks to me and I instruct her to increase the dose to 2 ½ pills.

19 Week 2 MD visit He is doing better; he feels no craving; medication dose seems to be lasting him 24 hours He will continue at this dose. I arrange an appointment with the substance abuse counselor

20 Substance Abuse Adjunctive counseling improves outcomes in substance abuse treatment (motivational enhancement initially and CBT later) * In-house substance abuse counselor for individual and group counseling Community or hospital based substance abuse treating organizations They sign a release so I or my staff could contact their counselors and make sure they are attending Considering having them carry a log to have it signed and dated by the counselor, then have the nurse call for verification every 2-4 weeks * Copenhaver, Bruce & Altice, AJDAA, 2007

21 Maintenance As the weeks go on, he complains of feeling down and being anxious. Cocaine is appearing in his urine BDI suggestive of depression (no evidence of bipolar disorder) and SSRI initiated After several weeks, his mood and anxiety symptoms have improved Positive cocaine urines becoming less frequent, but not absent

22 Yet his cocaine continues to be positive in urine. Suboxone is not a treatment for cocaine I meet with substance abuse counselor and we decide that IOP is best option for him at this point An alternative if resources are available is increased CBT Maintenance The three of us meet and we express our concern about his positive cocaine urines still present after 12 weeks of therapy and that we believe IOP would be better for him I will continue to prescribe him the suboxone but he needs to attend the IOP 3 times a week for enhanced counseling.

23 He had tested positive for HIV and Hep C infection. Co-Morbidities He was immediately referred to the Ryan White Program (HIV) nurse for intake. Work-up and possible treatment for Hep C discussed over the next several months. BP, glucose, lipids screened as well.

24 Urine tox screens done at every visit End Of Case While in in-house group, sees counselor weekly and sees provider monthly If outside counseling, visits are as often as provider deems necessary (usually every 1-2 weeks to start); these visits may be shared with nursing AA/NA meetings encouraged Mental health visits arranged if necessary Primary care, Hep C and HIV visits usually done with suboxone visits

25 Model Of Care Buprenorphine-prescribing physician (usually primary care provider but could be psychiatrist) Nursing +/- substance abuse counselor on site +/- mental health Have community resources where can send patients for substance abuse counseling or mental health

26 Need some administrative oversight of program and patients (resources) Limitations Need enhanced counseling to ensure sufficient integration of services onsite Cross-coverage for BPN prescription when providers absent

27 N = 257

28 N = 257

29 N = 257

30 N = 257

31 Summary BPN treatment can and should be integrated into Community Health Care Centers where opioid dependence is a problem. The various models that exist can be adapted (and improved upon) to fit each individual health center. May require some additional resources to optimally improve outcomes.

32 Contact Marwan Haddad, MD Community Health Center, Inc 134 State Street Meriden, CT

Medication Assisted Treatment. Nicole Gastala, MD

Medication Assisted Treatment. Nicole Gastala, MD Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants

More information

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral

More information

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine

More information

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin

More information

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE

More information

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE

AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE AN INTRODUCTION TO THE TREATMENT OF OPIOID USE DISORDERS IN PRIMARY CARE Valerie Carrejo, MD Assistant Professor UNM Family Medicine Advances in Primary Care April 14, 2017 Objectives Review the basic

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Substance Abuse Suboxone Treatment

Substance Abuse Suboxone Treatment Substance Abuse Suboxone Treatment Program Waterbury Hospital Infectious Disease Clinic Richard Smith, LCSW Leonard Savage, Consumer Steven I. Aronin, MD FACP, Program Director Ryan White All Grantee Meeting

More information

History of Present Illness (HPI) Assessment and Plan Template

History of Present Illness (HPI) Assessment and Plan Template History of Present Illness (HPI) Assessment and Plan Template Templates for induction and follow-up appointments for medication assisted treatment (MAT) in opioid use disorder (OUD). Consider saving this

More information

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Substitution Therapy for Opioid Use Disorder The Role of Suboxone Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

PATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone

PATIENT INTAKE: MEDICAL HISTORY. Name. Address. Phone (W) (H) (C) DOB Age SS# Emergency Contact. Relationship to patient Phone PATIENT INTAKE: MEDICAL HISTORY Name Address Phone (W) (H) (C) DOB Age SS# Emergency Contact Relationship to patient Phone Primary care physician Phone Have you ever had an EKG? Y N Date Current or past

More information

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5

More information

Buprenorphine as a Treatment Option for Opioid Use Disorder

Buprenorphine as a Treatment Option for Opioid Use Disorder Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital

More information

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers

More information

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives

More information

Opioid Dependence and Buprenorphine Management

Opioid Dependence and Buprenorphine Management Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale

More information

Medication Assisted Treatment

Medication Assisted Treatment Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

GOALS AND OBJECTIVES

GOALS AND OBJECTIVES SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES

More information

Medication-Assisted Treatment (MAT) Overview

Medication-Assisted Treatment (MAT) Overview Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for

More information

Vivitrol Drug Court and Medication Assisted Treatment

Vivitrol Drug Court and Medication Assisted Treatment Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment

More information

John Murphy DO, MS Lynx Healthcare

John Murphy DO, MS Lynx Healthcare Addiction to Pain Medication and Treatment John Murphy DO, MS Lynx Healthcare No Disclosures Objectives 1 Understand basic neurobiology and learning theory around opioid addiction 2 Identify aberrant behavior

More information

Buprenorphine treatment

Buprenorphine treatment South London and Maudsley NHS Foundation Trust Buprenorphine treatment Information for service users Page Buprenorphine treatment What is buprenorphine? Buprenorphine (trade name Subutex ) is an opioid

More information

Opioid Withdrawal, Opioid Substitution, and HIV Infection

Opioid Withdrawal, Opioid Substitution, and HIV Infection Opioid Withdrawal, Opioid Substitution, and HIV Infection R. Douglas Bruce, MD, MA, MS Associate Clinical Professor of Medicine Yale University New Haven, Connecticut Learning Objectives After attending

More information

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program

SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers

More information

Buprenorphine & Controlled Substance Treatment Agreement

Buprenorphine & Controlled Substance Treatment Agreement Buprenorphine & Controlled Substance Treatment Agreement I agree to accept the following treatment contract for buprenorphine office-based opioid addiction treatment: 1. I will keep my medication in a

More information

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008 Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality

More information

Prescription Opioid Addiction

Prescription Opioid Addiction CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett

More information

The Social Worker s Role in Medication Assisted Treatment

The Social Worker s Role in Medication Assisted Treatment The Social Worker s Role in Medication Assisted Treatment Rocky Ephraim Lucas, LICSW Behavioral Health Consultant, Kanawha City Health Center (Cabin Creek Health Systems) What is Medication-Assisted Treatment

More information

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health

More information

NURSING INTAKE. Provider Name: Provider Signature: Nursing Summary. Are you pregnant at this time?

NURSING INTAKE. Provider Name: Provider Signature: Nursing Summary. Are you pregnant at this time? NURSING INTAKE Provider Name: Provider Signature: Date: Nursing Summary Are you pregnant at this time? 3 = Don t know 4 = Tubal ligation 5 = Menopause 6 = History of hysterectomy 7 = Other: 8 = N/A patient

More information

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene

More information

OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL

OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL Brian Fuehrlein, MD PhD VA Connecticut Healthcare System and Yale University I have no conflicts of interest or relevant financial

More information

Talking with your doctor

Talking with your doctor SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may

More information

NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS

NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE BUPRENORPHINE/NALOXONE CLINIC VISITS Provider Name: NURSING FOLLOW-UP: BUPRENORPHINE/NALOXONE Provider Signature: Date: BUPRENORPHINE/NALOXONE CLINIC VISITS Once stable, schedule clinic visits every 2 to 4 weeks, with refills that coincide

More information

The Importance of Psychological Treatment and Behavioral Support

The Importance of Psychological Treatment and Behavioral Support The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose

More information

Opioid dependence and buprenorphine treatment

Opioid dependence and buprenorphine treatment Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are

More information

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL

More information

7/7/2016 Journal of the American Medical Association,

7/7/2016 Journal of the American Medical Association, 1 2 Journal of the American Medical Association, 2008 3 The Clinical Trial 152 Adolescents and Young Adults (Age 15 to 21) randomly assigned to either; 1. 2 weeks of Buprenorphine detox 2. 12 weeks of

More information

Building capacity for a CHC response to Ontario's Opioid Crisis

Building capacity for a CHC response to Ontario's Opioid Crisis Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC

More information

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence)

Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Hull & East Riding Prescribing Committee Prescribing Framework for Naltrexone in Relapse Prevention (Opioid Dependence) Patients Name: Unit Number: Patients Address:.. G.P s Name:.. Communication We agree

More information

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM Disclosures Dr. Bhatnagar: no disclosures to report Dr. Ewing: no disclosures to report 1 Our

More information

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January

More information

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full

More information

Acute General Medical and Surgical Admission:

Acute General Medical and Surgical Admission: Acute General Medical and Surgical Admission: Managing Substance Use Disorders in Patients Who are Severely Ill Scott Grantham, MD Executive Director, Behavioral Health Saint Francis Health System By the

More information

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone. 201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone. RELATES TO: KRS 311.530-311.620, 311.990 STATUTORY AUTHORITY: KRS

More information

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone) 9/9/2016 Prior Authorization Form PASSPORT HEALTH PLAN KENTUCKY MEDICAID Buprenorphine Products This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education

More information

SUBOXONE TREATMENT PROGRAM

SUBOXONE TREATMENT PROGRAM SUBOXONE TREATMENT PROGRAM What is Suboxone? Suboxone is a medication used for the treatment of addiction to prescription pain medication, heroin addiction, methadone or other opioid dependence. The primary

More information

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures

More information

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet

Now available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE

More information

Tuscarawas County Health Department. Vivitrol Treatment Consent

Tuscarawas County Health Department. Vivitrol Treatment Consent Tuscarawas County Health Department Vivitrol Treatment Consent I. Vivitrol Medication Guide: a. VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) b. Read this Medication Guide

More information

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian

More information

Treatment Alternatives for Substance Use Disorders

Treatment Alternatives for Substance Use Disorders Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict

More information

Controlled Substance and Wellness Agreement

Controlled Substance and Wellness Agreement Controlled Substance and Wellness Agreement You and your provider have agreed on the use of controlled substance medications to treat your: We want to make sure you know how to manage your new prescription(s)

More information

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description

More information

Buprenorphine Access in California

Buprenorphine Access in California Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance

More information

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication

More information

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased

More information

METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE

METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE Work with methadone clinic staff to coordinate the methadone taper, with the transition to buprenorphine/naloxone:

More information

Opioid Overdose Epidemic A Crises and Opportunity

Opioid Overdose Epidemic A Crises and Opportunity Opioid Overdose Epidemic A Crises and Opportunity Samuel M. Silverman MD, FAPA, DFASAM Assistant Clinical Professor, UConn Medical School Director, Medical Education Rushford, A Hartford HealthCare Partner

More information

Methadone Maintenance 101

Methadone Maintenance 101 Methadone Maintenance 101 OTP/DAILY DOSING CLINICS - ANDREW PUTNEY MD Conflicts of Interest - Employed by Acadia HealthCare 1 Why Methadone? At adequate doses methadone decreases opioid withdrawal symptoms

More information

Vermont Hub and Spoke Model Treatment Need Questionnaire

Vermont Hub and Spoke Model Treatment Need Questionnaire Vermont Hub and Spoke Model Treatment Need Questionnaire Friday, June 30, 2017 John Brooklyn, MD Assistant Professor of Family Medicine and Psychiatry University of Vermont Burlington, Vermont Webinar

More information

Opioid Withdrawal, Opioid Substitution Treatment, and HIV Infection

Opioid Withdrawal, Opioid Substitution Treatment, and HIV Infection Opioid Withdrawal, Opioid Substitution Treatment, and HIV Infection R. Douglas Bruce, MD, MA, MS Associate Clinical Professor of Medicine Yale University Chief of Medicine Cornell Scott-Hill Health Center

More information

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets

Suboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description

More information

Addiction vs. Dependence. Introduction. Methadone: Historical Background. Addiction vs. Dependence. C.O.R.E. Medical Clinic, Inc.

Addiction vs. Dependence. Introduction. Methadone: Historical Background. Addiction vs. Dependence. C.O.R.E. Medical Clinic, Inc. C.O.R.E. Medical Clinic, Inc. Chapter I Opioids and the Brain 2 Chapter Overview Introduction Addiction vs. Dependence Methadone: Historical Background Brain Chemistry: Before & After Opiate Use Methadone

More information

PATIENT TREATMENT CONTRACT

PATIENT TREATMENT CONTRACT Bridger Psychiatric Services, P.C. 2040 N. 22 nd Avenue, Ste. 2 Bozeman, MT 59718 406-586-5511 * 406-586-4713 (fax) PATIENT TREATMENT CONTRACT Patient Name Date As a participant in buprenorphine treatment

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

Medication Assisted Treatment:

Medication Assisted Treatment: Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications

More information

AODA RECOVERY. How to support those in recovery, and those not yet ready to commit

AODA RECOVERY. How to support those in recovery, and those not yet ready to commit AODA RECOVERY How to support those in recovery, and those not yet ready to commit YOUR PRESENTER TODAY Robin Lickel is a psychotherapist and addictions specialist at Journey Mental Health Center in Madison,

More information

Vivitrol Vs. Suboxone

Vivitrol Vs. Suboxone Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak

More information

The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016

The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016 The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine March 10, 2016 Objectives Review current state of opioid crisis in Maine Briefly review physiology of

More information

Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version

Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of

More information

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for

More information

Approaches to Treatment of Youth with Opioid Addiction

Approaches to Treatment of Youth with Opioid Addiction Approaches to Treatment of Youth with Opioid Addiction Marc Fishman MD Mountain Manor Treatment Center Johns Hopkins University What should we do with this case? 17 M Onset prescription opioids 15, progressing

More information

Methadone Treatment. in federal prison

Methadone Treatment. in federal prison INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional

More information

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to

More information

The Opioid-Exposed Woman

The Opioid-Exposed Woman The Opioid-Exposed Woman Management Considerations for Labor and Delivery Jane Sublette, MS, RN, CNM, WHNP-BC Fairview Ridges Hospital Objectives Describe opioid-associated risks to the mother and fetus

More information

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop

More information

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,

More information

Medication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 Amended Date: 10/1/2015 DRAFT Table of Contents

Medication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 Amended Date: 10/1/2015 DRAFT Table of Contents Medication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 10/1/2015 Table of Contents 1.0 Description of the Procedure, Product, or Service... 3 1.1 Definitions... 3 2.0 Eligibility Requirements...

More information

Opioid Use in Youth. Amy Yule M.D. March 2,

Opioid Use in Youth. Amy Yule M.D. March 2, Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin

More information

Integrating Buprenorphine Treatment for Opioid Use Disorder in Primary Care

Integrating Buprenorphine Treatment for Opioid Use Disorder in Primary Care Integrating Buprenorphine Treatment for Opioid Use Disorder in Primary Care BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH ALBERT EINSTEIN COLLEGE OF MEDICINE UCSF DEVELOPED WITH FUNDING FROM HEALTH RESOURCES

More information

Safe Practices and Action Items

Safe Practices and Action Items Safe Practices and Action Items Karen F Marlowe, Pharm D, BCPS Certified Pain Educator Auburn University Harrison School of Pharmacy University of South Alabama School of Medicine Case Study A 58 year

More information

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING

More information

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and

More information

Understanding Medication in Addiction Treatment for Drug Court Participants

Understanding Medication in Addiction Treatment for Drug Court Participants Understanding Medication in Addiction Treatment for Drug Court Participants Introduction This pocket guide is for drug court participants who may be prescribed or considering medication as a part of addiction

More information

Methadone Treatment. in federal prison

Methadone Treatment. in federal prison INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional

More information

Management of Opioid Use Disorder in Primary Care

Management of Opioid Use Disorder in Primary Care 1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,

More information

Opioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard

Opioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard Opioid Use in Pregnant Women and Prenatal Care Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard Objectives Summarize contextual and co-morbid factors observed among

More information

Optimizing Suboxone in Opioid Addicts

Optimizing Suboxone in Opioid Addicts Optimizing Suboxone in Opioid Addicts David Chim, D.O. Integrated Substance Abuse Programs Dept. of Psychiatry, UCLA K30 Translational Research Interest March 24, 2009 dchim@mednet.ucla.edu www.uclaisap.org

More information

Brief History of Methadone Maintenance Treatment

Brief History of Methadone Maintenance Treatment METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what

More information

ROSC & MAT II: Opioid Treatment Services

ROSC & MAT II: Opioid Treatment Services ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify

More information

An Adaptive Reinforcement-Based Treatment (RBT) Intervention for Pregnant Substance Dependent Women

An Adaptive Reinforcement-Based Treatment (RBT) Intervention for Pregnant Substance Dependent Women An Adaptive Reinforcement-Based Treatment (RBT) Intervention for Pregnant Substance Dependent Women Michelle Tuten, Ph.D. Assistant Professor Department of Psychiatry and Behavioral Sciences and Johns

More information